IBRX vs VNO · rev $51.2M vs rev $921.3M
Immunitybio Inc (IBRX) versus VNO (VNO) — a side-by-side from cached financials, not a winner call.
Immunitybio Inc (IBRX) is a biotechnology company listed on US.
VNO (VNO) common stock.
Latest reported IBRX revenue for 2026-06-30 was $51.2M. Net income was -$230.4M. Revenue was up 15.9% from 2026-03-31 to 2026-06-30. IBRX currently screens at market cap $7.88B.
Latest reported VNO revenue for 2026-06-30 was $921.3M. Net income was $24.6M. VNO currently screens at market cap $0.
IBRX currently screens at market cap $7.88B. VNO currently screens at market cap $0.
Not investment advice. Open the IBRX and VNO stock pages for the full models.
Not investment advice.